Research programme: osteoarthritis therapy - MIGENIX/University of California

Drug Profile

Research programme: osteoarthritis therapy - MIGENIX/University of California

Alternative Names: MITO 4042; MX 4042

Latest Information Update: 17 Oct 2007

Price : $50

At a glance

  • Originator MIGENIX
  • Developer MIGENIX; University of California, San Diego
  • Class
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 18 Apr 2006 This programme is still in active development
  • 22 Sep 2004 Micrologix Biotech is now called MIGENIX
  • 06 Sep 2004 MitoKor has been acquired and merged into Micrologix Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top